BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 29731134)

  • 1. Vogt-Koyanagi-Harada disease: study of 14 cases.
    Espinosa-Barberi G; Reyes Rodríguez MÁ; Francisco Hernández F
    Med Clin (Barc); 2019 Feb; 152(4):159-160. PubMed ID: 29731134
    [No Abstract]   [Full Text] [Related]  

  • 2. Vogt-Koyanagi-Harada syndrome: importance of early treatment.
    Radic B; Vukojevic N; Petelin Gadze Z; Dapic Ivancic B; Barun B
    Acta Neurol Belg; 2020 Oct; 120(5):1217-1219. PubMed ID: 31927745
    [No Abstract]   [Full Text] [Related]  

  • 3. Reversal of poliosis and vitiligo following Vogt-Koyanagi-Harada disease.
    Tabbara KF
    Arch Ophthalmol; 2012 Mar; 130(3):394-6. PubMed ID: 22411673
    [No Abstract]   [Full Text] [Related]  

  • 4. [Long-term course of immunosuppressive therapy of Vogt-Koyanagi-Harada syndrome].
    Wand K; Abraham S; Loos D; Stumpfe S; Lohmann C; Maier M; Feucht N
    Ophthalmologe; 2015 Oct; 112(10):857-60. PubMed ID: 25680347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Vogt-Koyanagi-Harada syndrome. Eight cases].
    Alaoui FZ; Benamour S; El Kabli H; Amraoui A
    Rev Med Interne; 2007 Apr; 28(4):250-4. PubMed ID: 17350144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrent anterior uveitis in patients with Vogt-Koyanagi-Harada syndrome.
    Taylor S; Lightman S
    Arch Ophthalmol; 2004 Jun; 122(6):922-3. PubMed ID: 15197072
    [No Abstract]   [Full Text] [Related]  

  • 7. Triple agent immunosuppressive therapy in Vogt-Koyanagi-Harada syndrome.
    Agarwal M; Ganesh SK; Biswas J
    Ocul Immunol Inflamm; 2006 Dec; 14(6):333-9. PubMed ID: 17162603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vogt-Koyanagi-Harada syndrome in two patients with immunoglobulin A nephropathy.
    Matsuo T; Masuda I; Ota K; Yamadori I; Sunami R; Nose S
    Acta Med Okayama; 2007 Oct; 61(5):305-9. PubMed ID: 17971847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclosporin therapy in Vogt Koyanagi Harada disease.
    Wakefield D; McCluskey P; Reece G
    Aust N Z J Ophthalmol; 1990 May; 18(2):137-42. PubMed ID: 2390240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Vogt-Koyanagi-Harada syndrome: report of a case].
    Lima JG; Robortella M; Atanes M; Reis Filho JB; Nobrega JA
    Arq Neuropsiquiatr; 1978 Mar; 36(1):67-71. PubMed ID: 637747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic corticosteroid treatment in Vogt-Koyanagi-Harada disease.
    Hayasaka S; Okabe H; Takahashi J
    Graefes Arch Clin Exp Ophthalmol; 1982; 218(1):9-13. PubMed ID: 7056483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased interleukin-37 expression in Vogt-Koyanagi-Harada disease and upregulation following immunosuppressive treatment.
    Ye Z; Wang C; Tang J; Zhou Y; Bai L; Liu Y; Kijlstra A; Yang P
    J Interferon Cytokine Res; 2015 Apr; 35(4):265-72. PubMed ID: 25343528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vogt-Koyanagi-Harada disease with meningitis-retention syndrome and increased CSF adenosine deaminase levels.
    Hiraga A; Takatsuna Y; Sakakibara R; Kamitsukasa I; Minamide M; Kuwabara S
    Clin Neurol Neurosurg; 2014 Dec; 127():42-3. PubMed ID: 25459241
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-lasting uveitis remission and hearing loss recovery after rituximab in Vogt-Koyanagi-Harada disease.
    Caso F; Rigante D; Vitale A; Costa L; Bascherini V; Latronico E; Franceschini R; Cantarini L
    Clin Rheumatol; 2015 Oct; 34(10):1817-20. PubMed ID: 25224382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Headache as a first manifestation of Vogt-Koyanagi-Harada disease.
    Kosma KK; Kararizou E; Markou I; Eforakopoulou E; Kararizos G; Mitsonis C; Gkiatas K
    Med Princ Pract; 2008; 17(3):253-4. PubMed ID: 18408397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vogt-Koyanagi-Harada syndrome.
    Ohno S; Char DH; Kimura SJ; O'Connor GR
    Am J Ophthalmol; 1977 May; 83(5):735-40. PubMed ID: 868972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reappraisal of the management of Vogt-Koyanagi-Harada disease: sunset glow fundus is no more a fatality.
    Herbort CP; Abu El Asrar AM; Yamamoto JH; Pavésio CE; Gupta V; Khairallah M; Tugal-Tutkun I; Soheilian M; Takeuchi M; Papadia M
    Int Ophthalmol; 2017 Dec; 37(6):1383-1395. PubMed ID: 27844182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Vogt-Koyanagi-Harada syndrome: apropos of 2 cases].
    Gabsi S; Hassoumi MH; Doss N; Mejri A; Othmani S; Bahri M
    Tunis Med; 1989 Dec; 67(12):817-20. PubMed ID: 2623779
    [No Abstract]   [Full Text] [Related]  

  • 19. [Vogt-Koyanagi-Harada syndrome in children].
    Laghmari M; Karim A; Ibrahimy W; Essakalli NH; Mohcine Z
    J Fr Ophtalmol; 2002 Jun; 25(6):636-40. PubMed ID: 12223954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Incomplete Vogt-Koyanagi-Harada syndrome associated with HLA DRB1*01 in a 4-year-old child: case report].
    Lucena DR; Paula JS; Silva GC; Rodrigues Mde L
    Arq Bras Oftalmol; 2007; 70(2):340-2. PubMed ID: 17589710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.